Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82,051,282
-
Total 13F shares
-
37,776,709
-
Share change
-
+9,428,888
-
Total reported value
-
$774,600,096
-
Put/Call ratio
-
26%
-
Price per share
-
$20.51
-
Number of holders
-
101
-
Value change
-
+$210,255,842
-
Number of buys
-
78
-
Number of sells
-
24
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q3 2022
As of 30 Sep 2022 Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) had 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 37,776,709 shares of stock of the company.
Largest 10 holders included COMMODORE CAPITAL LP, VR Adviser, LLC, BlackRock Inc., Deep Track Capital, LP, VANGUARD GROUP INC, BVF INC/IL, Vivo Capital, LLC, Paradigm Biocapital Advisors LP, Fairmount Funds Management LLC, and CITADEL ADVISORS LLC.
This table shows 102 institutional shareholders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.